Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
What adjuvant therapy, if any, would you offer for a young fit patient with stage IB lung adenocarcinoma harboring an EGFR A763_Y764insFQEA who received no prior therapy?
Related Questions
How would you approach Grade 2-3 rash due to erlotinib for a patient with metastatic EGFR mutated lung adenocarcinoma that is well controlled for > 5 years and NED by PET?
Would you consider stopping EGFR inhibitor in EGFR mutant NSCLC on a patient who was NED for >5 years?
Which patients with metastatic NSCLC with an EGFR mutation would you treat with chemotherapy & osimertinib or amivantamab & lazertinib, and how would you choose between the two regimens?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
In cases where EGFR NSCLC has transformed into small-cell lung cancer after treatment with Osimertinib, and with no CNS involvement, is it advisable to continue osimertinib alongside chemotherapy?
How would you approach local therapy (surgery or RT) in a patient with radiographic complete response after chemoimmunotherapy for non-small-cell lung cancer?
Would you consider adjuvant osimertinib for NSCLC with an EGFR E746_S752delinsV exon 19 mutation?
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
How do you sequence targeted therapy and immunotherapy in patients with metastatic lung adenocarcinoma with EGFR exon 20 insertion mutations?
What are your top takeaways from ESMO 2023?
